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Introduction
 Urothelial carcinoma (UC) is the fifth most common 
cancer throughout the world (Hatina and Schulz, 2012). 
Based on the report of the International Agency for 
Research on Cancer (GLOBOCAN 2008), there are 
about 386,000 new cases of urothelial bladder cancer and 
150,000 deaths annually worldwide (Ferlay et al., 2010; 
Hatina and Schulz, 2012). In Iran, bladder cancer is the 
third most common cancer among males and the ninth 
most common among females with an incidence of 13.03 
and 3.32 per 100000 population among men and women, 
respectively (Salehi et al., 2011). Several risk factors can 
cause bladder cancer including tobacco, non-occupational 
and industrial carcinogens, population aging, gender, 
residential area, consumption of contaminated water, 
family history of cancer, drinking tea and coffee, pelvic 
irradiation, cyclophosphamide, schistosomia infection or 
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Abstract
 Background: The aldehyde dehydrogenase 1 family member A1 (ALDH1A1) is one of the promising markers 
for identifying cancer stem cells in many cancer types, along with other markers including CD44. The aim of 
the present study was to evaluate the expression and clinical significance of putative cancer stem cell markers, 
CD44 and ALDH1A1, in a series of urothelial carcinomas of urinary bladder (UCUB) by tissue microarray 
(TMA). Materials and Methods: A total of 159 Urothelial Carcinomas (UC) including 96 (60%) low grade 
and 63 (40%) high grade carcinomas were immunohistochemically examined for the expression of CD44 and 
ALDH1A1. Correlations of the relative expression of these markers with clinicopathological parameters were 
also assessed. Results: High level expression of ALDH1A1 was found in 16% (25/159) of bladder UC which was 
significantly correlated with increased tumor size (p value=0.002), high grade (p value<0.001), pathologic stage 
(T1, p value=0.007 and T2, p value<0.001) and increased rate of recurrence (p value=0.013). A high level of CD44 
expression was found in 43% (68/159) of cases, being positively correlated with histologic grade (p value=0.032) 
and recurrence (p value=0.039). Conclusions: Taken together, our results showed that ALDH1 was concurrently 
expressed in a fraction of CD44+ tumors and its expression correlated with poor prognosis in UCs. ALDH1A1 
could be an ideal marker for targeted therapy of UCs in combination with conventional therapies, particularly 
in patients with high grade carcinomas. These findings indicate that cells expressing ALDH1A1 along with CD44 
can be a potential therapeutic target in bladder carcinomas. 
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chronic cystitis (Salehi et al., 2011; Ahmad et al., 2012; 
Ferris et al., 2013).
 Two different carcinogenic pathways also called dual 
track carcinogenesis are involved in the pathogenesis 
of UC including low-grade noninvasive papillary 
and high-grade flat-invasive sub-types (Brandt et al., 
2009; Hatina and Schulz, 2012). Low-grade (G1, G2) 
noninvasive papillary (pTa and pT1/pTis) UC account 
for approximately 70-80% of all bladder cancers which 
are caused by mutations in the fibroblast growth receptor 
(FGFR3) gene which causes activation of receptor tyrosine 
kinase-Ras pathway (Harvey Rasor PI3-kinase) (Billerey 
et al., 2001; van Rhijn et al., 2002; Wu, 2005; Su et 
al., 2010). Compared to low-grade tumors, the FGFR3 
mutation was not seen in high-grade (G3) flat- muscle 
invasive (greater than pT2) cancers which have the 
oncogenic mutations with loss of p53 and retinoblastoma 
(RB) tumor-suppressor gene activity (Cordon-Cardo et al., 
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1997; Cote et al., 1998; Wu, 2005; Brandt et al., 2009; Su 
et al., 2010). Half of patients diagnosed with high grade 
muscle-invasive UC progress to have metastases in the 
lungs and liver (Cordon-Cardo et al., 1997; Cote et al., 
1998; Brandt et al., 2009; Overdevest et al., 2011). High 
recurrence rate is another feature of urothelial carcinoma 
that can occur at every clinical stage (Brandt et al., 2009). 
It has been reported that the highest recurrence rate among 
all cancers is related to Urothelial carcinoma of urinary 
bladder (UCUB) which is attributed to the heterogeneous 
feature of cancer stem cells residing in the tumor (Yang 
and Chang, 2008). 
 Cancer stem cells (CSCs) or tumor-initiating cells 
are subpopulation of undifferentiated tumorigenic cells 
within the tumors that represent unique characteristics 
such as tumor-initiation, self-renewal, and the ability of 
proliferation which are responsible for tumor progression, 
relapse, metastasis and also tumor heterogeneity resulting 
from differentiation (Heppner, 1984; Reya et al., 2001; 
Clarke et al., 2006; Jordan et al., 2006; Dwyer et al., 
2007; Chang et al., 2008; Bentivegna et al., 2010; Su et 
al., 2010; Bohl et al., 2011; Ho et al., 2012; Madjd et al., 
2013). CSCs also mediate tumor resistance to common 
treatments such as chemotherapy and radiation (Bao et al., 
2006; Li et al., 2008; Bentivegna et al., 2010; Ho et al., 
2012; Madjd et al., 2013). In a large number of studies, 
CSCs have been isolated from patient specimens, cancer 
cell lines and xenografts using fluorescence-activated cell 
sorting (FACS) and with a combination of suitable cell 
surface markers, cytokeratin markers, drug transporters 
and side population (SP) in Hoechst 33342 staining (Yang 
and Chang, 2008; Su et al., 2010; Ho et al., 2012; Luo 
et al., 2012; Zhang et al., 2012). There are functionally 
distinct subpopulations of bladder CSCs which require 
further investigation to identify their cells of origin and 
self-renewal and differentiation features (Chan et al., 2010; 
Ho et al., 2012).
 Cancer stem cell markers including basal urothelial 
cell cytokeratins (CK5, CK14, CK17) (Ho et al., 2012) or 
adhesion molecules (CD44) (Immervoll et al., 2011; Ho et 
al., 2012), aldehyde dehydrogenase 1 family, member A1 
(ALDH1A1) (Ho et al., 2012), and tumor protein 63 (p63) 
(Ho et al., 2012) have been previously used as prognostic 
factors and applied to identify urothelial carcinoma stem 
cells (Hatina and Schulz, 2012; Ho et al., 2012). Further 
studies suggest that CSCs markers are composed of 
CD133 (Immervoll et al., 2008; Jaggupilli and Elkord, 
2012), CD24 (Jaggupilli and Elkord, 2012), CD90, CD34, 
CD117 and CD20 as other potential CSC markers in 
bladder carcinomas (Komuro et al., 2007; Mehrazma et 
al., 2013). CD44v6+/EMA- cells were used for isolating 
bladder CSCs in some studies (Yang and Chang, 2008; 
Chan et al., 2010; Ho et al., 2012).
 In addition, several Wnt signaling components 
are variously expressed in urothelial CSCs and non-
tumorigenic cancer cells, including Wnt10a ligand and 
the MYC oncogene (He et al., 2009). These components 
have been applied to distinguish urothelial CSCs from 
non-tumorigenic cancer cells (Urakami et al., 2006; Brandt 
et al., 2009). 
 ALDH1A1, a putative CSC marker, belongs to the 
ALDH1 family (Pearce et al., 2005; Balicki, 2007) and 
is expressed in normal and malignant human mammary 
stem cells (Ginestier et al., 2007); over expression of 
this marker is associated with poor prognosis in breast 
(Ginestier et al., 2007), bladder (Su et al., 2010) and lung 
cancers (Huang et al., 2009).
 CD44, a specific receptor for hyaluronic acid and 
adhesion/homing molecule (Naor et al., 2008; Jaggupilli 
and Elkord, 2012), is a multifunctional class I trans-
membrane glycoprotein expressed in almost all normal 
and cancer cells (Naor et al., 2008; Jaggupilli and Elkord, 
2012). In several previous studies, CD44 individually or 
in combination with other putative CSC markers has been 
applied to isolate CSCs in various solid tumors including 
breast (Al-Hajj et al., 2003), prostate, pancreas (Immervoll 
et al., 2011), ovarian, colorectal (Wielenga et al., 1993; 
Woodman et al., 1996; Choi et al., 2009), head and neck 
(Satpute et al., 2013) and bladder cancers (Yang and 
Chang, 2008; Chan et al., 2009; Slomiany et al., 2009; 
Lee et al., 2010; Su et al., 2010; Jaggupilli and Elkord, 
2012). Both in vitro and in vivo studies have shown that 
CD44+ bladder cancer cells have higher tumorigenic 
potential compared to CD44- bladder cancer cells; 
whereas they have lower tumorigenic potential compared 
to ALDH1A1+ cells (Su et al., 2010).
 Considering the absence of detailed reports focusing 
on the association between concurrent expression of two 
most frequent putative CSC markers ALDH1 and CD44 
with prognostic factors in UC of urinary bladder, in the 
present study we aimed to investigate the prognostic 
significance of these markers; also the prevalence of 
combined ALDH1/CD44 phenotype in a large scale series 
of Iranian UC of urinary bladder tumors using tissue 
microarray (TMA). This would help to determine the 
potential utility of the combination of these two molecular 
markers in the targeted therapy of bladder cancers.
Materials and Methods
Patients and specimens
 Tumor samples from 159 paraffin embedded UC of 
urinary bladder of patients underwent either transurethral 
resection of bladder tumor (TURB-BT, 81%) or bladder 
biopsy (19%) were assembled in tissue microarray format. 
All patients were diagnosed between 2008 and 2009 
(mean follow up of 46 months) in Hasheminejad Kidney 
Center, a major referral university-based Urology hospital 
in Tehran, Iran. Medical records and clinicopathologic 
features including tumor size, tumor grade, lamina propria 
invasion, muscular invasion, and pathologic tumor stage of 
cases were collected and recorded in the database (Table 
1). 
 Follow-up data regarding the date and cause of death 
for part of (120 cases) this cohort of patients has been 
provided prospectively, since the specimen collected form 
national referral hospital , some patients of other cities 
could not be followed. Follow-up was calculated from the 
date of operation, and all surviving cases were censored for 
survival analysis at 31 Sep 2013. None of these patients 
received adjuvant chemotherapy or radiation therapy 
before surgery. Tissue sections (4-µm thick) were obtained 
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from each block, stained with Hematoxylin and Eosin 
(H&E), and reviewed independently by two pathologists 
(H. K. & M. A.) to confirm the diagnosis and the presence 
of tumor. The best area for preparing TMA of each samples 
were determined after reviewing all H&E stained slides. 
Furthermore, normal bladder specimens were obtained 
from non-cancerous bladder biopsy specimens, which 
were used as normal controls and included in TMAs to 
compare the staining patterns of ALDH1 and CD44 in a 
range of different tissue samples.
 Tumor grade was determined according to 2004 
WHO grading system (Grignon, 2009). The staging of 
UC was assessed according to AJCC (American joint 
committee on cancer) (Cheng et al., 2009). Patients’ data 
were fully anonymous. This research study was approved 
by Iran University of Medical Sciences Research Ethics 
Committee.
Immunohistochemistry (IHC)
 Immunohistochemical staining was performed on 
TMA slides (Superfrost plus, Thermo Scientific, Germany) 
prepared from formalin-fixed paraffin-embedded 
tissues (FFPE) using a protocol as previously described 
(Mohsenzadegan et al., 2013; Taeb et al., 2014). Briefly, 
after deparaffinizationin xylene, tissues were rehydrated by 
immersion in decreasing grades of ethanol and endogenous 
peroxidase activity was blocked by immersing the tissues 
for 20 min in methanol containing 0.3% hydrogen 
peroxide and retrieved by boiling in a microwave for 20 
minutes with sodium citrate buffer (pH 6.0). To detect 
ALDH1A1 and CD44 staining in tissue sections, after 
antigen-retrieval, tissues were incubated overnight with 
primary antibodies including rabbit monoclonal antibody 
(mAb) to ALDH1A1 (Abcam 52492, UK) and CD44 (NE 
12 8 EW, Novocastra, UK) with optimal dilution of 1:200 
and 1:40, respectively. After washing with Tris-Buffered 
Saline (TBS), tissues were incubated in the secondary 
antibody which was EnVisionTM+/HRP, Dual Link 
Rabbit/Mouse (Dako, Denmark) for 15 minutes at room 
temperature. The slides were then washed with TBS, and 
the antigens were visualized by 10 minutes incubation with 
the addition of 3, 3’-diaminobenzidine (DAB, Dako). In 
the final step, tissue sections were lightly counterstained 
with haematoxylin (Dako), dehydrated in alcohol, cleared 
in xylene (Dako) and mounted for visualization. The entire 
tissues of tonsil and liver specimen were used as positive 
controls for CD44 and ALDH1A1 antibodies, respectively. 
Negative control, consisting of TBS instead of primary 
antibody, confirmed the specificity of the staining.
Preparing tissue microarray (TMA) 
 Tissue microarray blocks were prepared as described 
previously (Kononen et al., 1998; Mehrazma et al., 
2013). In each case, 5-µm H and E slides were used 
to mark out representative areas of tumor tissue. From 
each corresponding paraffin-embedded block, five 
representative tumor regions were marked to cover 
heterogenicity of expression of ALDH1A1. Cores with a 
diameter of 0.6 mm were punched from selected regions 
of each ‘‘donor’’ block and precisely arrayed into a new 
recipient paraffin block using Tissue Arrayer Minicore 
(ALPHELYS, Plaisir, France). Tissue microarray (TMA) 
blocks were constructed in five copies for each specimen; 
the mean scoring of five cores was then calculated as the 
final score (Camp et al., 2000). 
Evaluation of immunostaining
 The staining intensity of antibodies were evaluated 
applying a semi-quatitaive system, ranging from negative 
to strong; 0 (negative), 1 (weak), 2 (moderate), and 3 
(strong staining), by one pathologist (HK) after a series 
was observed on a multi-headed microscope by other 
observer (ZM) in a coded manner. In controversy cases, 
the scoring was confirmed by two observers and an 
agreement achieved. The percentage of positive cells for 
each antibody was graded as: 1 (<25% positive cells), 
2 (25-50% positive cells), 3 (50-75% positive cells), 4 
(>75% positive cells). The overall score was calculated 
by H-score (Histochemical score) for each case by 
multiplying the intensity of staining by the percentage 
of positive cells and a final score of 0 to 300 was given 
(McCarty et al., 1985). The mean of H-scores was 
chosen as cut-off value to classify the samples as high 
or low expression. The cut off value found to be 8.5 for 
Table 1. Association between ALDH1A1 and CD44 Expression (Intensity, Percentage of Positive Cells and 
H-Score) and Clinicopathological Parameters of Bladder Cancer (p value; Pearson χ2)
Patients and tumor  Expression of ALDH1A1 (p value; Pearson χ2) Expression of CD44 (p value; Pearson χ2)
characteristics  No. of  Intensity Percentage of H-score Intensity of Percentage of H-score
  cases (%) of staining positive cells (cut-off=8.5) staining positive cells (cut-off=90)
All cases  159      
Age (years) <64 75 (47) 0.006 0.153 0.074 0.38 0.597 0.446
 >64 84 (53)      
Gender Male 138 (87) 0.45 0.675 0.118 0.609 0.85 0.4
 Female 21 (13)      
Tumor Grade High 63 (40) <0.001 0.046 <0.001 0.899 0.032 0.305
 Low 96  (60)      
Tumor Size(cm) <3 124 (78) 0.002 0.604 0.066 0.367 0.36 0.432
 >3 35 (22)      
Tumor Recurrence Yes 21 (13) 0.013 0.269 0.135 0.039 0.211 0.159
 No 138  (87)      
Lamina propriainvasion Present 41 (26) 0.007 0.4 <0.001 0.408 0.252 0.503
 Absent 118 (74)      
Muscularinvasion Present 13  (8) <0.001 0.069 0.019 0.33 0.487 0.289
 Absent 146 (92)      
Hossein Keymoosi et al
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ALDH1A1 and 90 for CD44.
Statistical analysis
 The data were analyzed using the SPSS statistical 
software package version 20 (SPSS Inc, ChicagoIL, 
USA). Pearson’s χ2 and Pearson’s R tests were used to 
analyze the significance of correlation between expression 
of two putative CSC markers, ALDH1A1 and CD44 and 
clinicopathologic variables. Survival rates were examined 
by the Kaplan-Meier method for analysis of censored data. 
The statistical significance of differences between the 
survivals rates of groups with different expression of these 
markers were analyzed using the log-rank test. Patients 
whose deaths related to bladder cancer were considered in 
the disease-specific survival calculations. Deaths resulting 
from non bladder cancer related causes were censored at 
the time of death. A p value of <0.05 was considered to 
be statistically significant.
Results 
Study population and demographic features of patient
 A total of 173 patients which diagnosed with Urothelial 
carcinoam of urinary bladder (UCUB) were collected for 
this study. Due to technical problems in tissue processing 
or absence of tumor cells within the cores, 14 samples 
were excluded from the study, leaving 159 tumors for final 
scoring. Of this collection, 138 (87%) cases were male 
and 21 (13%) cases were female (M:F ratio was 6.57). 
The mean age at the time of diagnosis was 64±12 years 
(range 23-87 years).
 Follow up data were available for 120 patients, from 
whom 94 cases were still alive and 22 were deceased 
from non-bladder cancer related causes, only 4 cases had 
died from cancer related disease. The median length of 
follow-up available for surviving patients was 49 months 
(range 1-77 months).
 Seventy five (47%) patients were less than 64 year 
age, whereas 84 (53%) cases were older than mean age. 
In terms of histologic grade, 96 (60%) of tumors were 
low grade, whereas 63 (40%) of tumors were high grade. 
Tumor size ranged 0.3-6 cm (mean= 2.3 cm) in largest 
diameter. In 124 (78%) cases, tumor size was less than 
3cm (cut off= 3 cm) in the largest diameter and 35 (22%) 
tumors were more than 3cm (Cheng et al., 2009). Of this 
series of patients, in 41(26%) of cases the lamina propria 
were involved and 13 (8%) tumors showed muscular 
invasion. The recurrence of disease was observed in 
21 (13%) of patients, while other 138 (87%) cases had 
no recurrence. The clinicopathologic and demographic 
features of patients, tumor characteristics and tissue 
involvement data are summarized in Table 1. 
Expression of ALDH1A1 and CD44 in UCUB
 Immunohistochemical analysis of two putative 
stem cell markers, ALDH1 and CD44, was performed 
on a series of 159 paraffin embedded UCUB samples 
which were included in TMA. Level of expression was 
assessed by three scoring methods; intensity of staining, 
percentage of positive cells, and H-score. Normal liver 
and tonsil tissues, which were used as positive controls for 
ALDH1 and CD44 antibodies, showed strong and uniform 
staining (Figure 1 A, B). Staining of ALDH1 was mainly 
cytoplasmic, whereas CD44 was mainly expressed on the 
cell membrane of tumor cells (Figure 2 A, B). Only 33% 
(52/159) of TMA cores stained with ALDH1, whereas 
the majority of tumors (67%) were negative for ALDH1 
staining. Among the tumors stained with ALDH1, weak, 
moderate and strong intensity was observed in 6 % (10), 
11% (17) and 16 % (25) of samples, respectively (Table 
2). In contrast, CD44 was expressed in 87% (139/159) 
of tumors and only 13% (20) of cases did not show any 
staining. Weak, moderate and strong staining of CD44 
were observed in 24% (39), 39% (62) and 24% (38) of 
tumors, respectively (Figure 3) (Table 2). The average 
intensity of CD44 expression (mean= 1.7) was higher than 
ALDH1 expression (mean= 0.7). Similarly, the overall 
staining (H-score) of CD44 (mean= 90) was also higher 
than H-score of ALDH1 (mean H-score= 8.5).
Association of ALDH1 expression with clinicopathological 
parameters
 Higher level of expression of ALDH1A1 was observed 
in 16% (25 of 159) of UCUB. Univariate analysis showed 
a significant correlation between expression of ALDH1 in 
terms of intensity of staining (p value<0.001), percentage 
of positive cells (p value=0.046) and H-score (cut-off= 
8.5, p value<0.001) with tumor grade, indicating that 
higher level of ALDH1expression was more often found 
in high grade tumors. Moreover, the stronger intensity 
of ALDH1 was significantly associated with age (p 
value=0.006), increased tumor size (p value=0.002), 
lamina propria involvement (p value=0.007), muscular 
invasion (p value<0.001), and increased rate of recurrence 
Table 2. Expression of ALDH1A1 and CD44 (intensity, percentage of positive cells and H-score) in UCUB
Pattern of expression Intensity of staining Percentage of positive cells H-score
   cut-off=8.5(ALDH1A1)
   cut-off=90(CD44)
  Negative Weak Moderate Strong <25 25-50 50-75 >75 Low High
Expression of ALDH1 No (%) 10 9(67) 10 (6) 17 (11) 25 (16) 154(97) 3 (2) 0 (0) 2 (1) 134 (84) 25 (16)
Expression of CD44 No (%) 20 (13) 39 (24) 62 (39) 38 (24) 57 (36) 49 (31) 31 (19) 22 (14) 91 (57) 68 (43)
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Figure 1. Expression of ALDH1A1 and CD44 Proteins 
Observed in Normal Controls. (A) Normal liver for 
ALDH1A1: ×20, (B) Normal tonsil for CD44: ×20
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(p value=0.013). Similarly, the overall staining of ALDH1 
(H-score) was positively correlated with lamina propria 
involvement (p value<0.001), muscular invasion (p 
value=0.019), and a relative association with tumor size 
(p value=0.066).
 Low expression of ALDH1A1 (in terms of H-score) 
was significantly correlated with T1 stage (p value<0.001), 
whereas moderate and strong expression of ALDH1A1 
showed highly significant correlation with T2 stage (p 
value<0.001).
 There was no significant correlation with age (p 
value=0.074), gender (p value=0.118) and tumor 
recurrence (p value=0.135).
 In contrast, on Kaplan-Meier analysis, no association 
was found between ALDH1 expression and patient 
survival (log rank test, p value=0.159).
Association of CD44 expression with clinicopathological 
parameters
 High level of CD44 expression (intensity) was 
found in 43% (68 of 159) of UCUB samples, which 
was significantly correlated with higher histologic grade 
(p value=0.032), and recurrence (p value=0.039). To 
assess the clinical significance of CD44 expression in 
bladder cancer patients, we used H-score (cut-off= 90) 
to determine whether a high or low expression of CD44 
expression was correlated with clinicopathologic features. 
However, there was no significant association between 
overall staining of CD44 (H-score) and clinicopathologic 
features such as patient’s age (p value=0.44), gender (p 
value=0.40), tumor grade (p value=0.30), tumor size (p 
value=0.43), lamina propria involvement (p value=0.50), 
muscular invasion (p value=0.28), and tumor recurrence 
(p value=0.15). Similarly, no significant association was 
evident between CD44 expression and survival on Kaplan-
Meier analysis (log rank test, p value=0.444).
Combined analysis of ALDH1/CD44
 Comparing the results for both CSC markers ALDH1 
and CD44, a significant reciprocal pattern of expression 
was seen (p value<0.001). Combined analysis of 
the expression of these two markers indicated that a 
total of 47/159 (30%) cases displayed the ALDH1+/
CD44+ phenotype, occurring more frequently in poor 
prognosis tumors. Strong correlation was found between 
ALDH1+/CD44+ phenotype and high grade tumors (p 
value<0.001), larger tumor size (p value=0.013), lamina 
propria involvement (p value=0.002), muscular invasion 
(p value<0.001), and tumor recurrence (p value<0.001) 
on univariete analysis. Whereas 9% (15/159) of tumors 
showed ALDH1-/CD44- phenotype, 58% (92/159) of 
cases were ALDH1-/CD44+ phenotype, and just 3% 
(5/159) of tumors possessed ALDH1+/CD44- phenotype.
 Kaplan-Meier analysis did not reveal a significant 
survival advantage in ALDH1 high/CD44 high phenotype 
tumors compared with the remaining cases (log rank test, 
p value=0.115).
Discussion
Studies on phenotypic and functional properties of 
urothelial CSCs revealed that these cells can be identified 
by a panel of markers. Among various and proposed 
cancer stem cell surface markers used to isolate different 
subtypes of urothelial carcinomas, ALDH1A1 is one of the 
promising prognostic markers for CSCs of UCUB (Hatina 
and Schulz, 2012; Ho et al., 2012). In the present study, 
we examined the immunohistochemical expression of two 
putative cancer stem cell markers, CD44 and ALDH1A1, 
using tissue microarray method for the first time among 
159 Iranian patients suffering from UCUB and then we 
evaluated the correlation between expressions of each 
marker with clinicopathological parameters. Our finding 
showed that high expression of ALDH1A1 was found in 
16% of bladder cancers which was significantly correlated 
with high grade carcinomas, older patients, increased rate 
of tumor stage and recurrence. 
Therefore, overexpression of ALDH1A1 was 
positively associated with clinicopathological and 
prognostic factors of bladder cancers indicating that 
ALDH1A1 could be applied as a prognostic marker in 
urothelial carcinomas. 
Only two studies have been previously performed on 
bladder cancer regarding ALDH1A1 which revealed the 
prognostic value of ALDH1A1 for urothelial carcinomas. 
In Su et al study ALDH1A1+ cells isolated from bladder 
cancer cells with Aldefluorassay and the expression 
of ALDH1A1 in bladder tissues examined using 
immunohistochemistry method. Significant association 
was found between high expression of ALDH1A1 in 
patients with bladder urothelial carcinomas and tumor 
progression compared to those with low expression of 
ALDH1A1 (Su et al., 2010). In another study on the 
prognostic value of the ALDH1A3 and HOXA9, ISL1 as 
novel methylation markers was evaluated using microarray 
Figure 2. Cytoplasmic Expression of ALDH1A1 
Proteinobserved in Bladder Carcinomas. (A) Strong 
with original magnification: ×20 (B) moderate with original 
magnification: ×20
2A×20 2B×20 
Figure 3. Cell Membrane Staining of CD44 Observed 
in Bladder Carcinomas. (A) Strong with original 
Magnification: ×20, (B) Moderate with original Magnification: 
×20
3A×20 3B×20 
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analysis of DNA methylation and RNA expression patterns 
in non-muscle invasive bladder cancer (NMIBC) (Kim et 
al., 2013). Our study in a series of Iranian UCUB patients 
reveals the same characteristics of ALDH1A1 expression 
in urothelial carcinomas as previous studies in western 
populations. In a review performed by Januchowski 
et al, the association between high level expression of 
ALDH1A1 and poor prognosis was shown in breast (Black 
et al., 2009; Tanei et al., 2009), bladder (Su et al., 2010) 
and prostate cancer patients (Li et al., 2010). It has also 
been shown to be a marker of CSCs in many types of solid 
tumors, including liver (Lingala et al., 2010), head and 
neck (Clay et al., 2010), pancreas (Rasheed et al., 2010), 
lung (Rasheed et al., 2010) ovary (Deng et al., 2010), and 
colon carcinomas (Lugli et al., 2010). Similar results were 
reported by Tanei et al in another study on breast cancer 
indicating the association between high expression of 
ALDH1A1 with lower overall survival and increase the 
number of ALDH1A1+ cells after chemptherapy (Tanei 
et al., 2009), since chemotherapy cannot eradicate cancer 
stem cells (CSCs) expressing ALDH1A1. Moreover 
another study performed by Deng et al. using tissue array 
of serous ovarian cancers showed that high expression 
of ALDH1A1 was correlated with shorter disease-free 
and overall survival times compared to those with low 
ALDH1A1(Deng et al., 2010). Recently, ALDH1A1 has 
been reported to be an independent prognostic factor for 
patient free survival and overall survival in astrocytomas 
(Liu et al., 2012). Our findings showed that only 33% 
of TMA cores stained with ALDH1A1 and high level 
expression of ALDH1A1 was found in 16% of samples, 
whereas the majority of tumors (67%) were negative for 
ALDH1A1. These results support that the ALDH1A1+ 
cancer cells constitute only a small fraction of cancer 
stem cells in bladder cancer. Our study was also consistent 
with other IHC studies illustrating that ALDH1A1 was 
expressed mainly in cytoplasm of 26% of bladder tumors 
(Su et al., 2010), 30% of breast tumors (Ginestier et al., 
2007), and 29% of lung cancers (Jiang et al., 2009).
Since the assessment of markers in combination 
may perform better than those considered individually, 
therefore, we emphasize the prognostic value of 
combined ALDH1/CD44 status in bladder UCUB. Our 
data from combined analysis of both ALDH1A1/CD44 
showed that 30% of urothelial carcinomas displayed the 
ALDH1A1+/CD44+ phenotype; whereas 58% of cases 
were ALDH1A1-/CD44+ phenotype and only 3% tumors 
expressed ALDH1A1+/ CD44- phenotype. This finding 
suggests that the ALDH1A1+ population is a subset of 
the CD44+ bladder cancer cells.
In conclusion, ALDH1A1, a bladder CSC associated 
marker is a potential prognostic factor for identifying and 
treatment of high grade urothelial carcinomas. Therefore, 
it can be used as a new marker for localized targeting of 
CSCs (with monoclonal antibodies against ALDH1A1) 
and thus control of the tumor in advanced cases. Further 
stratification of patients by combined ALDH1+/CD44+ 
phenotype identifies a subset of bladder cancer patients 
for whom more aggressive treatment is appropriate. 
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